NCT05301062View on ClinicalTrials.gov

A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels

TerminatedOBSERVATIONAL
Enrollment

8

Participants

Timeline

Start Date

September 15, 2022

Primary Completion Date

April 28, 2023

Study Completion Date

June 30, 2023

Conditions
Metastatic Castration-resistant Prostate CancerBone Metastases
Interventions
DRUG

Radium-223 dichloride (Xofigo, BAY88-8223)

Treatment with Radium-223 should follow the approved local product information according to National Medical Products Administration (NMPA) approved label

Trial Locations (1)

Unknown

Many locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT05301062 - A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels | Biotech Hunter | Biotech Hunter